Development of a novel glycoengineering platform for the rapid production of conjugate vaccines.
Bacterial vaccines
Bioconjugation
Conjugate vaccines
Glycoengineering
Journal
Microbial cell factories
ISSN: 1475-2859
Titre abrégé: Microb Cell Fact
Pays: England
ID NLM: 101139812
Informations de publication
Date de publication:
18 Aug 2023
18 Aug 2023
Historique:
received:
05
05
2023
accepted:
10
06
2023
medline:
21
8
2023
pubmed:
19
8
2023
entrez:
18
8
2023
Statut:
epublish
Résumé
Conjugate vaccines produced either by chemical or biologically conjugation have been demonstrated to be safe and efficacious in protection against several deadly bacterial diseases. However, conjugate vaccine assembly and production have several shortcomings which hinders their wider availability. Here, we developed a tool, Mobile-element Assisted Glycoconjugation by Insertion on Chromosome, MAGIC, a novel biotechnological platform that overcomes the limitations of the current conjugate vaccine design method(s). As a model, we focused our design on a leading bioconjugation method using N-oligosaccharyltransferase (OTase), PglB. The installation of MAGIC led to at least twofold increase in glycoconjugate yield via MAGIC when compared to conventional N-OTase based bioconjugation method(s). Then, we improved MAGIC to (a) allow rapid installation of glycoengineering component(s), (b) omit the usage of antibiotics, (c) reduce the dependence on protein induction agents. Furthermore, we show the modularity of the MAGIC platform in performing glycoengineering in bacterial species that are less genetically tractable than the commonly used Escherichia coli. The MAGIC system promises a rapid, robust and versatile method to develop vaccines against serious bacterial pathogens. We anticipate the utility of the MAGIC platform could enhance vaccines production due to its compatibility with virtually any bioconjugation method, thus expanding vaccine biopreparedness toolbox.
Identifiants
pubmed: 37596672
doi: 10.1186/s12934-023-02125-y
pii: 10.1186/s12934-023-02125-y
pmc: PMC10436394
doi:
Substances chimiques
Vaccines, Conjugate
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
159Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBSRC BB/H017437/1
Pays : United Kingdom
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Rosini R, Nicchi S, Pizza M, Rappuoli R. Vaccines against antimicrobial resistance. Front Immunol. 2020;3:1048.
doi: 10.3389/fimmu.2020.01048
Rappuoli R. Glycoconjugate vaccines: Principles and mechanisms. Sci Transl Med. 2018. https://doi.org/10.1126/scitranslmed.aat4615 .
doi: 10.1126/scitranslmed.aat4615
pubmed: 30158151
Dow JM, Mauri M, Scott TA, Wren BW. Improving protein glycan coupling technology (PGCT) for glycoconjugate vaccine production. Expert Rev Vaccines. 2020;19(6):507–27. https://doi.org/10.1080/14760584.2020.1775077 .
doi: 10.1080/14760584.2020.1775077
pubmed: 32627609
Avci FY, Li X, Tsuji M, Kasper DL. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med. 2011. https://doi.org/10.1038/nm.2535 .
doi: 10.1038/nm.2535
pubmed: 22101769
pmcid: 3482454
Kay E, Cuccui J, Wren BW. Recent advances in the production of recombinant glycoconjugate vaccines. npj Vaccines. 2019. https://doi.org/10.1038/s41541-019-0110-z .
doi: 10.1038/s41541-019-0110-z
pubmed: 31069118
pmcid: 6494827
Poolman J, Frasch C, Nurkka A, Käyhty H, Biemans R, Schuerman L. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol. 2010;18(2):327–36. https://doi.org/10.1128/CVI.00402-10 .
doi: 10.1128/CVI.00402-10
pubmed: 21123523
pmcid: 3067356
Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thöny-Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact. 2010. https://doi.org/10.1186/1475-2859-9-61 .
doi: 10.1186/1475-2859-9-61
pubmed: 20701771
pmcid: 2927510
Koffas MAG, Linhardt RJ, Natarajan A, Jaroentomeechai T, Li M, Glasscock CJ, et al. Metabolic engineering of glycoprotein biosynthesis in bacteria. Emerg Top Life Sci. 2018;2(3):419–32.
doi: 10.1042/ETLS20180004
Cuccui J, Thomas RM, Moule MG, D’Elia RV, Laws TR, Mills DC, et al. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. Open Biol. 2013. https://doi.org/10.1098/rsob.130002 .
doi: 10.1098/rsob.130002
pubmed: 23697804
pmcid: 3866875
Herbert JA, Kay EJ, Faustini SE, Richter A, Abouelhadid S, Cuccui J, et al. Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine. Vaccine. 2018;36(26):3809. https://doi.org/10.1016/j.vaccine.2018.05.036 .
doi: 10.1016/j.vaccine.2018.05.036
pubmed: 29778517
pmcid: 5999350
Strutton B, Jaffé SRP, Pandhal J, Wright PC. Producing a glycosylating Escherichia coli cell factory: the placement of the bacterial oligosaccharyl transferase pglB onto the genome. Biochem Biophys Res Commun. 2018;495(1):686–92. https://doi.org/10.1016/j.bbrc.2017.11.023 .
doi: 10.1016/j.bbrc.2017.11.023
pubmed: 29113801
Dykxhoorn DM, St. Pierre R, Linn T. A set of compatible tac promoter expression vectors. Gene. 1996. https://doi.org/10.1016/0378-1119(96)00289-2 .
doi: 10.1016/0378-1119(96)00289-2
pubmed: 8921858
Oyston PCF, Sjostedt A, Titball RW. Tularaemia: Bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol. 2004. https://doi.org/10.1038/nrmicro1045 .
doi: 10.1038/nrmicro1045
pubmed: 15550942
Scott NE, Parker BL, Connolly AM, Paulech J, Edwards AVG, Crossett B, et al. Simultaneous glycan-peptide characterization using hydrophilic interaction 2 chromatography and parallel fragmentation by CID, HCD and ETD-MS applied to the N- 3 linked glycoproteome of Campylobacter jejuni. Am Soc Biochem Mol Biol. 2010. https://doi.org/10.1074/mcp.M000031-MCP201 .
doi: 10.1074/mcp.M000031-MCP201
Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci. 2005. https://doi.org/10.1073/pnas.0500044102 .
doi: 10.1073/pnas.0500044102
pubmed: 16243969
pmcid: 1276087
Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018. https://doi.org/10.1038/s41579-018-0001-8 .
doi: 10.1038/s41579-018-0001-8
pubmed: 29599457
pmcid: 5949087
Gao F, Lockyer K, Burkin K, Crane DT, Bolgiano B. A physico-chemical assessment of the thermal stability of pneumococcal conjugate vaccine components. Hum Vaccines Immunother. 2014. https://doi.org/10.4161/hv.29696 .
doi: 10.4161/hv.29696
Kay EJ, Yates LE, Terra VS, Cuccui J, Wren BW. Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli. Open Biol. 2016. https://doi.org/10.1098/rsob.150243 .
doi: 10.1098/rsob.150243
pubmed: 27110302
pmcid: 4838161
Kelly JR, Rubin AJ, Davis JH, Ajo-Franklin CM, Cumbers J, Czar MJ, et al. Measuring the activity of BioBrick promoters using an in vivo reference standard. J Biol Eng. 2009. https://doi.org/10.1186/1754-1611-3-4 .
doi: 10.1186/1754-1611-3-4
pubmed: 19298678
pmcid: 2683166
Berti F, De Ricco R, Rappuoli R. Role of o-acetylation in the immunogenicity of bacterial polysaccharide vaccines. Molecules. 2018. https://doi.org/10.3390/molecules23061340 .
doi: 10.3390/molecules23061340
pubmed: 30142938
pmcid: 6225197
Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982–2002. Emerg Infect Dis. 2005;11(4):603. https://doi.org/10.3201/eid1104.040739 .
doi: 10.3201/eid1104.040739
pubmed: 15829201
pmcid: 3320345
Vinogradov E, Conlan JW, Perry MB. Serological cross-reaction between the lipopolysaccharide O-polysaccharaide antigens of Escherichia coli O157:H7 and strains of Citrobcter freundii and Citrobacter sedlakii. FEMS Microbiol Lett. 2000;190(1):157–61. https://doi.org/10.1111/j.1574-6968.2000.tb09279.x .
doi: 10.1111/j.1574-6968.2000.tb09279.x
pubmed: 10981707
Bandyopadhyay AS, Singh H, Fournier-Caruana J, Modlin JF, Wenger J, Partridge J, et al. Facility-associated release of polioviruses into communities—risks for the posteradication. Emerg Infect Dis. 2019;25(7):1363. https://doi.org/10.3201/eid2507.18170 .
doi: 10.3201/eid2507.18170
pubmed: 31082331
pmcid: 6590745
Stefanetti G, Okan N, Fink A, Gardner E, Kasper DL. Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to Francisella tularensis. Proc Natl Acad Sci. 2019;116(14):7062–70.
doi: 10.1073/pnas.1900144116
pubmed: 30872471
pmcid: 6452683
2020 WHO Global Vaccine Market Report. https://www.who.int/publications/m/item/2020-who-global-vaccine-market-report . Accessed 28 Sep 2021.
Stark JC, Jaroentomeechai T, Moeller TD, Hershewe JM, Warfel KF, Moricz BS, et al. On-demand biomanufacturing of protective conjugate vaccines. Sci Adv. 2021. https://doi.org/10.1126/sciadv.abe9444 .
doi: 10.1126/sciadv.abe9444
pubmed: 34533989
pmcid: 8448442
Schoborg JA, Hershewe JM, Stark JC, Kightlinger W, Kath JE, Jaroentomeechai T, et al. A cell-free platform for rapid synthesis and testing of active oligosaccharyltransferases. Biotechnol Bioeng. 2018;115(3):739–50. https://doi.org/10.1002/bit.26502 .
doi: 10.1002/bit.26502
pubmed: 29178580
Neuhard J, Thomassen E. Altered deoxyribonucleotide pools in P2 eductants of Escherichia coli K 12 due to deletion of the dcd gene. J Bacteriol. 1976;126(2):999. https://doi.org/10.1128/jb.126.2.999-1001.1976 .
doi: 10.1128/jb.126.2.999-1001.1976
pubmed: 177407
pmcid: 233240
Alaimo C, Catrein I, Morf L, Marolda CL, Callewaert N, Valvano MA, et al. Two distinct but interchangeable mechanisms for flipping of lipid-linked oligosaccharides. EMBO J. 2006;25(5):967.
doi: 10.1038/sj.emboj.7601024
pubmed: 16498400
pmcid: 1409731
Garcia-Quintanilla F, Iwashkiw JA, Price NL, Stratilo C, Feldman MF. Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery. Front Microbiol. 2014. https://doi.org/10.3389/fmicb.2014.00381 .
doi: 10.3389/fmicb.2014.00381
pubmed: 25120536
pmcid: 4114197
De Lorenzo V, Herrero M, Jakubzik U, Timmis KN. Mini-Tn5 transposoon derivatives for insertion mutagenesis, promoter probing, and chromosomal insertion of cloned DNA in gram-negative eubacteria. J Bacteriol. 1990. https://doi.org/10.1128/jb.172.11.6568-6572.1990 .
doi: 10.1128/jb.172.11.6568-6572.1990
pubmed: 2172217
pmcid: 526846
Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci U S A. 2005;102(8):3016–21.
doi: 10.1073/pnas.0500044102
pubmed: 15703289
pmcid: 549450